Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2605541 (Insulin Peglispro) Adipose Tissue PK Study
NCT02109029Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2014
- Primary completion
- Mar 2015
- Modality
- Polymer-based Nanoparticles, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of insulin peglispro in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Pharmacokinetics: Steady-State Concentrations in Adipose Tissue Interstitial Fluid (ISF) at 28 hours and Pharmacokinetics: ISF-to-Serum Concentrations at 28 hours. Started Apr 2014; status: completed.
02
Drugs
insulin peglispro
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02109029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02109029.